Alternatively, an aptamer-based targeting of NCL, which has garnered significant attention of late [25,26,27], may be an attractive approach for the treatment of breast cancers with aberrant AEG-1 expression. This evidence concerns the gene NUCLEOLIN and breast carcinoma.